This study followed seven adult patients with both PSC and ulcerative colitis. All patients were treated for at least six months with oral vancomycin doses between 250 mg – 1,500 mg per day.

All patients achieved clinical remission with their ulcerative colitis. Labs that decreased included: fecal calprotectin, C-reactive protein, the Mayo score, alkaline phosphatase, and total bilirubin.

Additionally, no patient treated with oral vancomycin developed VRE or reported any adverse events.